U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H16N4O4.ClH
Molecular Weight 304.73
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXRAZOXANE HYDROCHLORIDE

SMILES

Cl.C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2

InChI

InChIKey=BIFMNMPSIYHKDN-FJXQXJEOSA-N
InChI=1S/C11H16N4O4.ClH/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14;/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19);1H/t7-;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf

Dexrazoxane is a cardioprotective drug used in patients with breast cancer to reduce cardiomyopathy associated with doxorubicin administration. Dexrazoxane is believed to act by two mechanisms: it inhibits DNA topoisomerase II and acts as a chelator for iron ions.

CNS Activity

Originator

Approval Year

1995
196
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 13.0 µM [IC50]
Chelating Agent
142
 17.4 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8429
ZINECARD

Approved Use

Zinecard is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control.

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
337 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29273587
60 mg/kg single, intraperitoneal
dose: 60 mg/kg
route of administration: Intraperitoneal
experiment type: SINGLE
co-administered:
DEXRAZOXANE plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
838 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29273587
60 mg/kg single, intraperitoneal
dose: 60 mg/kg
route of administration: Intraperitoneal
experiment type: SINGLE
co-administered:
DEXRAZOXANE plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
500 mg/m² single, intravenous
dose: 500 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: DOXORUBICIN
DOXORUBICIN
 DEXRAZOXANE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29273587
60 mg/kg single, intraperitoneal
dose: 60 mg/kg
route of administration: Intraperitoneal
experiment type: SINGLE
co-administered:
DEXRAZOXANE plasma
Oryctolagus cuniculus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
500 mg/m² single, intravenous
dose: 500 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered: DOXORUBICIN
DOXORUBICIN
 DEXRAZOXANE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg/m2 1 times / 4 weeks multiple, intravenous (total)
MTD
Dose: 250 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/11410492/
unhealthy, 57 years (range: 46-76 years)
n = 22
Health Status: unhealthy
Condition: advanced malignancies
Age Group: 57 years (range: 46-76 years)
Sex: M+F
Population Size: 22
Sources:
https://pubmed.ncbi.nlm.nih.gov/11410492/
Disc. AE: Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (grade 4, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11410492/
900 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 900 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 900 mg/m2, 1 times / 3 weeks
Co-administed with::
doxorubicin(60 mg/m^2; 1/3 week)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: advanced malignancies
Age Group: adult
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (4 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
600 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 600 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 600 mg/m2, 1 times / 3 weeks
Co-administed with::
doxorubicin(60 mg/m^2; 1/3 week)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
unhealthy, adult
n = 9
Health Status: unhealthy
Condition: advanced malignancies
Age Group: adult
Sex: M+F
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (4 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Other AEs: Alopecia, Nausea...
Other AEs:
Alopecia (100%)
Nausea (51%)
Vomiting (42%)
Malaise and fatigue (48%)
Anorexia (27%)
Stomatitis (26%)
Fever (22%)
Infection (19%)
Diarrhea (14%)
Injection site pain (13%)
Sepsis (12%)
Neurotoxicity (10%)
Erythema (4%)
Phlebitis (3%)
Esophagitis (3%)
Hemorrhage (3%)
Extravasation (3%)
Urticaria (2%)
Administration site recall reaction (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Other AEs: Alopecia, Nausea...
Other AEs:
Alopecia (94%)
Nausea (77%)
Vomiting (59%)
Malaise and fatigue (61%)
Anorexia (42%)
Stomatitis (34%)
Fever (34%)
Infection (23%)
Diarrhea (21%)
Injection site pain (12%)
Sepsis (17%)
Neurotoxicity (17%)
Erythema (5%)
Phlebitis (6%)
Esophagitis (6%)
Dysphagia (8%)
Hemorrhage (2%)
Extravasation (1%)
Urticaria (2%)
Administration site recall reaction (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Thrombocytopenia grade 4, 2 patients
Disc. AE
250 mg/m2 1 times / 4 weeks multiple, intravenous (total)
MTD
Dose: 250 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 250 mg/m2, 1 times / 4 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/11410492/
unhealthy, 57 years (range: 46-76 years)
n = 22
Health Status: unhealthy
Condition: advanced malignancies
Age Group: 57 years (range: 46-76 years)
Sex: M+F
Population Size: 22
Sources:
https://pubmed.ncbi.nlm.nih.gov/11410492/
Neutropenia 4 patients
DLT
900 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 900 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 900 mg/m2, 1 times / 3 weeks
Co-administed with::
doxorubicin(60 mg/m^2; 1/3 week)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
unhealthy, adult
n = 6
Health Status: unhealthy
Condition: advanced malignancies
Age Group: adult
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
Neutropenia 4 patients
DLT
600 mg/m2 1 times / 3 weeks multiple, intravenous
RP2D
Dose: 600 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 600 mg/m2, 1 times / 3 weeks
Co-administed with::
doxorubicin(60 mg/m^2; 1/3 week)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
unhealthy, adult
n = 9
Health Status: unhealthy
Condition: advanced malignancies
Age Group: adult
Sex: M+F
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/1433357/
Administration site recall reaction 1%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Neurotoxicity 10%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Alopecia 100%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Sepsis 12%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Injection site pain 13%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Diarrhea 14%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Infection 19%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Urticaria 2%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Fever 22%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Stomatitis 26%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Anorexia 27%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Esophagitis 3%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Extravasation 3%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Hemorrhage 3%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Phlebitis 3%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Erythema 4%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Vomiting 42%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Malaise and fatigue 48%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Nausea 51%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 102
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 102
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Administration site recall reaction 1%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Extravasation 1%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Injection site pain 12%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Neurotoxicity 17%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Sepsis 17%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Hemorrhage 2%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Urticaria 2%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Diarrhea 21%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Infection 23%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Fever 34%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Stomatitis 34%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Anorexia 42%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Erythema 5%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Vomiting 59%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Esophagitis 6%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Phlebitis 6%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Malaise and fatigue 61%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Nausea 77%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Dysphagia 8%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Alopecia 94%
500 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 500 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 500 mg/m2, 1 times / day
Co-administed with::
doxorubicin(50 mg/m^2)
fluorouracil
cyclophosphamide
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
unhealthy, adult
n = 413
Health Status: unhealthy
Condition: breast cancer
Age Group: adult
Sex: F
Population Size: 413
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-1307
http://www.3bsc.com/index/pro_info.php?id=55023
AA Blocks
AA002OL7
https://www.aablocks.com/goods/Goods/detail?id=AA002OL7
AEchem Scientific Corp., USA
AE1-014835
http://www.aechemsc.com/info_products/AE1-014835.php
AHH Chemical co.,ltd
MT-49873
http://www.ahhchemical.com/product/MT-49873.html
AK Scientific, Inc. (AKSCI)
69488
http://www.aksci.com/item_detail.php?cat=69488
AK Scientific, Inc. (AKSCI)
J90038
http://www.aksci.com/item_detail.php?cat=J90038
Aaron Chemicals
AR002PCZ
http://www.aaronchem.com/24584-09-6
Acadechem
ACDS-062689
http://www.acadechemical.com/product/137388
Achemo Scientific Limited
AC-74299
http://www.achemo.com/search/?Keyword= 24584-09-6
Achemtek
0104-020754
http://www.achemtek.com/24584-09-6
Alfa Chemistry
AP24584096
https://reagents.alfa-chemistry.com/product/dexrazoxane-cas-24584-09-6-8513.html
Ambinter
Amb22744843
http://www.ambinter.com/reference/22744843
Angene
AGN-PC-0O877E
http://www.angenechemical.com/productshow/AGN-PC-0O877E.html
Anward
ANW-44923
http://www.anward.com/pro_result/31374
ApexBio Technology
A1602
http://www.apexbt.com/dexrazoxane-hcl-icrf-187-adr-529.html
AstaTech, Inc.
25916
http://www.astatechinc.com/CPSResult.php?CRNO=29109
Aurora Fine Chemicals LLC
A17.905.381
http://online.aurorafinechemicals.com/info?ID=A17.905.381
Aurum Pharmatech LLC
MP-0159
http://www.Aurumpharmatech.com/Product/ProductDetails/MP_0159
AvaChem Scientific
3082B
http://www.avachem.com/productSearch.asp?3082B
Avantor Inc
TCD4227-100MG
https://us.vwr.com/store/product/16811739/dexrazoxane-98-0-by-titrimetric-analysis
BLD Pharm
BD123889
http://www.bldpharm.com/products/24584-09-6.html
BioSynth
J-015579
https://www.biosynth.com/en/products/all-products/products/J-015579.html
BioSynth
J-520219
https://www.biosynth.com/en/products/all-products/products/J-520219.html
CSNpharm
CSN10785
https://www.csnpharm.com/products/dexrazoxane.html
Chem Scene
CS-2769
http://www.chemscene.com/24584-09-6.html
ChemMol
49408757
http://www.chemmol.com/chemmol/49408757.html
Chemenu
CM120112
http://www.chemenu.com/products/CM120112
Chemspace
CSSB00000054680
https://chem-space.com/CSSB00000054680
DAOGE BIOPHARMA
DG21-14309
https://www.daogechem.com/product/24584-09-6.html
Glentham Life Sciences
GP2739
http://www.glentham.com/products/product/GP2739/
Huateng Pharma
F80010873
http://en.huatengsci.com/product/Dexrazoxane.html
Lab Network
LN00337707
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00337707
Matrix Scientific
126235
https://www.matrixscientific.com/126235.html
MedChem Express
HY-B0581
https://www.medchemexpress.com/dexrazoxane.html
MuseChem
I002831
https://www.musechem.com/product/I002831.html
OChem
6570
http://www.ocheminc.com/index.php?act=psearch&pid=584D096
Oakwood
93447
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=78621&ExtHyperLink=1
Parchem
28706
http://www.parchem.com/chemical-supplier-distributor/Dexrazoxane-018706.aspx
Renno Tech
RP29555
http://www.rennotech.com/product_show.asp?id=35162
Sigma-Aldrich
05587_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/05587?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
D1446_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/d1446?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S047032
http://www.sinfoobiotech.com/product/1050430
Smolecule
S548609
http://www.smolecule.com/products/s548609
TCI (Tokyo Chemical Industry)
D4227
http://www.tcichemicals.com/eshop/en/us/commodity/D4227/index.html
THE BioTek
bt-288014
https://www.thebiotek.com/product/inhibitors/bt-288014
Yuhao Chemical
LT4788
http://www.chemyuhao.com/24584-09-6.html
abcr GmbH
AB436257
http://www.abcr.com/shop/en/AB436257
eNovation Chemicals
D672527
https://www.enovationchem.com/ProductDetails.asp?ProductID=D672527
eNovation Chemicals
D764439
https://www.enovationchem.com/ProductDetails.asp?ProductID=D764439
eNovation Chemicals
Y0980546
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0980546
iChemical
EBD45155
http://www.ichemical.com/products/24584-09-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression.
2003 Dec 20
Protein profiling in daunorubicin-induced cardiomyopathy.
2003 Sep
Iron chelators in cancer chemotherapy.
2004
Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
2004 Apr
Cardiotoxicity of cytotoxic drugs.
2004 Apr
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
2004 Dec 2
Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo.
2004 Dec 24
Mitoxantrone treatment of multiple sclerosis: safety considerations.
2004 Dec 28
Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions.
2004 Feb
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
2004 Jul 8
[Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
2004 Jun
[Dexrazoxane and cardiotoxicity in repeatedly treated patients].
2004 Jun
Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
2004 Jun
Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing.
2004 May
Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
2004 Nov
[Cardiac prevention: the oncologic point of view].
2004 Nov
Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
2004 Nov
The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
2004 Nov
Concurrent therapies that protect against doxorubicin-induced cardiomyopathy.
2004 Oct
Accelerated approval of oncology products: a decade of experience.
2004 Oct 20
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
2004 Sep
The prevention and management of cardiovascular complications of chemotherapy in patients with cancer.
2005
Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
2005
Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
2005
Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits.
2005 Apr
Molecular pharmacology of the interaction of anthracyclines with iron.
2005 Aug
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
2005 Dec
Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
2005 Dec
The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
2005 Jan
Cardioprotective interventions for cancer patients receiving anthracyclines.
2005 Jan 25
Monitoring cardiac function in patients receiving doxorubicin.
2005 Jul
CD95/Apo-1/Fas: independent cell death induced by doxorubicin in normal cultured cardiomyocytes.
2005 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
2005 Jun
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
2005 Jun 15
Gender-dependent reductions in vertebrae length, bone mineral density and content by doxorubicin are not reduced by dexrazoxane in young rats: effect on growth plate and intervertebral discs.
2005 Mar
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
2005 May 15
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
2005 Nov
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
2005 Oct 1
Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats.
2005 Sep
Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
2005 Sep
Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors.
2005 Sep 15
Clinical nurse specialist and evidence-based practice: managing anthracycline extravasation.
2005 Sep-Oct
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.
2006 Apr
Altered responsiveness of the guinea-pig isolated ileum to smooth muscle stimulants and to electrical stimulation after in situ ischemia.
2006 Feb
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
2006 Feb
Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase.
2006 Feb 15
Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
2006 Feb 8
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
2006 Jan
Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.
2006 Jan
Patents

Patents

JP2006519264A
58
JP2007511507A
5
JP2011527579A
29
JPS6463577A
2

Sample Use Guides

In Vivo Use Guide
The recommended dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g., 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin). Do not administer doxorubicin before dexrazoxane.
Route of Administration: Intravenous
In Vitro Use Guide
Human osteoblasts P2 cells and Human ginigiva fibroblasts P2 cells were treated with zoledronic acid (50 umol/L) and the cytoprotectant dexrazoxane (600 umol/L). At that concentration dexrazoxane showed significant cytoprotective effect.
Name Type Language
DEXRAZOXANE HYDROCHLORIDE
ORANGE BOOK   VANDF   WHO-DD  
Common Name English
DEXRAZOXANE HYDROCHLORIDE [VANDF]
Common Name English
RAZOXANE (+)-FORM HYDROCHLORIDE [MI]
Common Name English
ZINECARD
Brand Name English
Dexrazoxane hydrochloride [WHO-DD]
Common Name English
2,6-PIPERAZINEDIONE, 4,4'-((1S)-1-METHYL-1,2-ETHANEDIYL)BIS-, HYDROCHLORIDE (1:1)
Systematic Name English
ICRF-187 HYDROCHLORIDE
Code English
(+)-RAZOXANE HYDROCHLORIDE
Common Name English
RAZOXANE HYDROCHLORIDE, (S)-
Common Name English
TOTECT
Brand Name English
DEXRAZOXANE HCL
Common Name English
ADR-529 HYDROCHLORIDE
Code English
SAVENE
Brand Name English
CARDIOXAN
Brand Name English
2,6-PIPERAZINEDIONE, 4,4'-(1-METHYL-1,2-ETHANEDIYL)BIS-, HYDROCHLORIDE, (S)-
Common Name English
CARDIOXANE
Brand Name English
DEXRAZOXANE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS SAVENE (AUTHORIZED: EXTRAVASTATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS)
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
NCI_THESAURUS C62357
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
FDA ORPHAN DRUG 441314
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
Code System Code Type Description
FDA UNII
5346058Q7S
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
RXCUI
1294534
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
Dexrazoxane hydrochloride
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
NCI_THESAURUS
C66945
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
EVMPD
SUB01631MIG
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
CHEBI
50224
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
MERCK INDEX
m9511
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY Merck Index
DAILYMED
5346058Q7S
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
DRUG BANK
DBSALT001028
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
EPA CompTox
DTXSID60164152
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
CAS
149003-01-0
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
NON-SPECIFIC STOICHIOMETRY
ChEMBL
CHEMBL1738
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
PUBCHEM
6918223
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
SMS_ID
100000090557
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
CAS
1263283-43-7
Created by admin on Fri Dec 15 15:56:42 GMT 2023 , Edited by admin on Fri Dec 15 15:56:42 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of DEXRAZOXANE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966